
... BIBLIOGRAPHY ...

- Adelman JU, Sharfman M, Johnson R et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. *Am J Man Care* 1996; 2:1407-1416.
- Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. *Headache* 1992;32:101-104.
- American Academy of Neurology Quality Standards Subcommittee. Practice parameter: The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). *Neurology* 1994;44:1353.
- Anderson DW, ed. *Neuroepidemiology: A Tribute to Bruce Scheinberg*. Boca Raton, FL: CRC Publishers; 1991.
- Balfour JA, Bryson HM. Valproic acid. A review of its pharmacology and therapeutic potential in indications other than epilepsy. *CNS Drugs* 1994;2:144-173.
- Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults. *Psychiatry Res* 1991;37:11-23.
- Cameron ME. Headaches in relation to the eyes. *Med J Aust* 1986;1:292-294.
- Clouse JC, Osterhaus JT. Health care resource use and costs associated with migraine in a managed health care setting. *Ann Pharmacother* 1994;28:659-663.
- Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences. *Family Medicine* 1996;28:171-177.
- Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. *Ann Emerg Med* 1995;26:541-546.
- Coukell AJ, Lamb HM. Sumatriptan: A pharmacoeconomic review of its use in migraine. *PharmacoEconomics* 1997;11:473-490.
- Deaton RL, Thomas JR. The efficacy of divalproex sodium prophylactic treatment in patients experiencing migraine with or without aura. *Cephalalgia* 1995;15:268 (Abstract)
- Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. *Arch Fam Med* 1998;7:234-240.
- Essink-Bot ML, van Royen L, Krabbe P, et al. The impact of migraine on health status. *Headache* 1995;35(4):200-206.
- Faffenrath P, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptans. *Headache* 1998;38:184-190.
- Ferrari M, and the Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. *N Engl J Med* 1991;325:316-321.
- Fisher MA, Glass S. Butorphanol (Stadol): A study in the problems of current drug information and control. *Neurology* 1997;48:1156-1160.
- Gallagher RM, for the Dihydroergotamine Working Group. Acute treatment of migraine with dihydroergotamine nasal spray. *Arch Neurol* 1996;53:1285-1291.
- Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. *Arch Neurol* 1996;53:1285-1291.
- Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. *Cephalalgia* 1997;17:647-651.
- Graff-Radford SB, Dieter S. Headache related to temporomandibular structures. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. *The Headaches*. New York: Raven Press, 1993:759.
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 1998;8(suppl 7):1-96.
- Henry P, Michel P, Brochet B. A nationwide survey of migraine in France: Prevalence and clinical features in adults. *Cephalalgia* 1992;12:229-237.
- Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Arch Neurol* 1997;54:1141-1145.
- Klapper JA. Divalproex sodium in migraine prophylaxis: A dose-controlled study. *Cephalalgia* 1997;17:103-108.
- Klassen A, Elkind MD, Asgharnejad M, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. *Headache* 1997;37:640-645.

... BIBLIOGRAPHY ...

- Lipton RB, Stewart WF. Migraine in the United States: Epidemiology and health care utilization. *Neurology* 1993;43:6-10
- Lipton RB, Stewart WF, von Korff M. The burden of migraine: A review of cost to society. *Pharmacoeconomics* 1994;6:215-221.
- Lipton RB, Stewart WF, von Korff M. The burden of migraine: A review of cost to society. *Pharmacoeconomics* 1997;11:473-490.
- Lipton RB, Stewart WF, von Korff M. Burden of migraine: Societal cost and therapeutic opportunities. *Neurology* 1997;48 (Suppl 3):S4-S9.
- Lipton RB, Stewart WF. Clinical applications of zolmitriptan (Zomig, 311C90). *Cephalalgia* 1997;17(suppl 18):53-59.
- Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. *Headache* 1994;34:319-328.
- Lipton RB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. *Neurology* 1993;43(suppl 3):S6-S10.
- Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headache: A comparison of symptom-based and reported physician diagnosis. *Arch Intern Med* 1992;152:1273-1278
- Lipton, RB. Migraine: Prevalence and impact. Migraine occupational health seminar. 1996. Conference Proceedings.
- Louis I, Olesen J. Evaluation of pericranial tenderness and oral function in patients with common migraine, muscle contraction headache, and combination headache. *Pain* 1982;12:285-392.
- Markley HG, Cleronis JCD, Piepko RW. Verapamil prophylactic therapy of migraine. *Neurology* 1984;34:973-976.
- Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3003 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study. *Neurology* 1997;49:1485-1490.
- Mathew NT, Saper JR, Silberstein SD, et al. Prophylaxis of migraine headaches with divalproex sodium. *Arch Neurol* 1995;52:281-286.
- Migranal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 1997.
- Naratriptan. [package insert]. Raleigh-Durham, NC: Glaxo Wellcome; 1998
- Novartis Pharmaceuticals Corporation, East Hanover, NJ. Dihydroergotamine information. 1998. Data File.
- Osterhaus JT, Gutterman DL, Plachetka JR. Health care resource and lost labour cost of migraine headache in the US. *Pharmacoeconomics* 1992;2:67-76.
- Osterhaus J T, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. *Headache* 1994;34(6):337-343.
- Osterhaus JT, Gutterman DL, Plachetka JR. Health care resources and lost labor costs of migraine headache in the US. *Pharmacoeconomics* 1992;2:67-76.
- Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. *Drugs* 1998;55:889-922
- Ptradalier A, Hannard P, Sellers E, Bringer L. Migraine and glaucoma: An epidemiologic survey of French ophthalmologists. *Cephalalgia* 1998;18:74-76.
- Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: Proof of efficacy, utilization and cost. *Cephalalgia* 1997;17:73-80.
- Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population: A prevalence study. *J Clin Epidemiol* 1991;44:1147-1157
- Ryan R, Elkind A, Baker CC, Mullican W, DeBussey BS, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. *Neurology* 1997;49:1225-1230.
- Salonen R, Ashford E, Dahlöf, et al for the International Intranasal Sumatriptan Study Group. Intranasal sumatriptan for the acute treatment of migraine. *J Neurol* 1994; 241:463-469.
- Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: Chronic daily headache and migraine. *Headache* 1994;34:497-502.
- Schoenen J. Acute migraine therapy: The newer drugs. *Curr Opin Neurol* 1997;10:237-243.
- Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. *Neurology* 1998;50:466-470.
- Schönsted-Madsen U, Stoksted P, Christensen PH, Koch-Henriksen N. Chronic headache related to nasal obstruction. *J Laryngol Otol* 1986;100:165-170.
- Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. *Arch Intern Med* 1996;156:1725-1728.
- Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. *Headache* 1997;37:S15-S25

... BIBLIOGRAPHY ...

- Silberstein SD, Lipton RB, Breslau N. Migraine: Association with personality characteristics and psychopathology. *Cephalalgia* 1995;15:337-369.
- Silberstein SD, Saper JR. Migraine: Diagnosis and treatment. In: Dalessio DJ, Silberstein SD, eds. *Wolff's Headache and Other Head Pain*. 6th ed. New York: Oxford University Press, 1993:96-170.
- Silberstein SD, Lipton RB, Goadsby PJ. *Headache in Clinical Practice*. Oxford, England: Isis Medical Media Ltd., 1998.
- Smith R. Management of chronic headache. *Can Fam Physician* 1998;35:1835-1839.
- Rappoport AM, Ramadan NM, Adelman JU, et al, on behalf of The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. *Neurology* 1997;49:1210-1218.
- Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the medical outcomes study instrument. *Headache* 1994;34(3):143-147.
- Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM on behalf of the 042 Clinical Trial Study Group. *Neurology* 1997;49:1219-1225.
- Solomon GD. Management of the headache patient with medical illness. *Clin J Pain* 1989;5:95-99.
- Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: A double-blind, placebo-controlled study. *JAMA* 1983;250:2500-2502.
- Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the U.S.: Relation to age, income, race and other sociodemographic factors. *JAMA* 1992;267:64-69.
- Stewart WF, Lipton RB, Simon D. Work-related disability: Results from the American Migraine Study. *Cephalalgia* 1996;16:231-238.
- Sumatriptan IN. [package insert]. Raleigh-Durham, NC: Glaxo Wellcome; 1998.
- Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAX-ALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. *Headache* 1998;38:281-287.
- The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. *Eur Neurol* 1991;31:332-338.
- Visser WH, deVriend RH, Jaspers MW, Ferrari MD. Sumatriptan in clinical practice: A 2-year review of 453 migraine patients. *Neurology* 1996;47:46-51.
- Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. *Headache* 1997;37:377-382.
- Welch KMA. Drug therapy of migraine. *N Engl J Med* 1993;329:1476-1483.
- Wilkinson M, Pfaffenroth V, Schoenen J, Diener H-C, Steiner TJ. Migraine and cluster headache. Their management with sumatriptan: A critical review of the current clinical experience. *Cephalalgia* 1995;15:337-357.
- Zolmitriptan [package insert]. Wilmington, DE: Zeneca Pharmaceuticals; 1998.